INNOVIVA, INC. Interest and Dividend Income, Operating
INNOVIVA, INC. (INVA) reported Interest and Dividend Income, Operating of $7.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InterestAndDividendIncomeOperating · last filed 2026-08-05
- INNOVIVA, INC. interest and dividend income, operating for the quarter ending 2026-06-30 was $7.60M, a 54.29% increase year-over-year.
- INNOVIVA, INC. interest and dividend income, operating for the quarter ending 2026-03-31 was $10.99M, a 142.11% increase year-over-year.
- INNOVIVA, INC. interest and dividend income, operating for the quarter ending 2025-12-31 was $6.15M, a 6.64% increase year-over-year.
- INNOVIVA, INC. interest and dividend income, operating for the quarter ending 2025-09-30 was $5.47M, a 0.51% decline year-over-year.
- INNOVIVA, INC. interest and dividend income, operating for fiscal 2025 was $21.09M, a 10.16% increase from fiscal 2024.
- INNOVIVA, INC. interest and dividend income, operating for fiscal 2024 was $19.14M, a 21.01% increase from fiscal 2023.
- INNOVIVA, INC. interest and dividend income, operating for fiscal 2023 was $15.82M, a 148.36% increase from fiscal 2022.
- INNOVIVA, INC. interest and dividend income, operating for fiscal 2022 was $6.37M, a 246.33% increase from fiscal 2021.
| Period end | Interest and Dividend Income, Operating 3 month | Interest and Dividend Income, Operating 6 month | Interest and Dividend Income, Operating 9 month | Interest and Dividend Income, Operating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.60M 10-Q · filed 2026-08-05 | $18.59M 10-Q · filed 2026-08-05 | $24.74M derived: sum of 3 quarters · filed 2026-08-05 | $30.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.99M 10-Q · filed 2026-05-06 | $17.14M derived: sum of 2 quarters · filed 2026-05-06 | $22.61M derived: sum of 3 quarters · filed 2026-05-06 | $27.54M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.62M derived: sum of 2 quarters · filed 2026-02-25 | $16.55M derived: sum of 3 quarters · filed 2026-08-05 | $21.09M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.47M 10-Q · filed 2025-11-05 | $10.40M derived: sum of 2 quarters · filed 2026-08-05 | $14.94M 10-Q · filed 2025-11-05 | $20.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.92M 10-Q · filed 2026-08-05 | $9.46M 10-Q · filed 2026-08-05 | $15.23M derived: sum of 3 quarters · filed 2026-08-05 | $20.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.54M 10-Q · filed 2026-05-06 | $10.31M derived: sum of 2 quarters · filed 2026-05-06 | $15.81M derived: sum of 3 quarters · filed 2026-05-06 | $19.28M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.27M derived: sum of 2 quarters · filed 2026-02-25 | $14.74M derived: sum of 3 quarters · filed 2026-02-25 | $19.14M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.50M 10-Q · filed 2025-11-05 | $8.97M derived: sum of 2 quarters · filed 2025-11-05 | $13.37M 10-Q · filed 2025-11-05 | $18.16M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.47M 10-Q · filed 2025-08-06 | $7.87M 10-Q · filed 2025-08-06 | $12.66M derived: sum of 3 quarters · filed 2026-02-25 | $16.77M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $4.40M 10-Q · filed 2025-05-07 | $9.19M derived: sum of 2 quarters · filed 2026-02-25 | $13.30M derived: sum of 3 quarters · filed 2026-02-25 | $16.85M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.90M derived: sum of 2 quarters · filed 2026-02-25 | $12.45M derived: sum of 3 quarters · filed 2026-02-25 | $15.82M 10-K · filed 2026-02-25 |
| 2023-09-30 | $4.11M 10-Q · filed 2024-11-06 | $7.67M derived: sum of 2 quarters · filed 2024-11-06 | $11.03M 10-Q · filed 2024-11-06 | $14.22M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $3.55M 10-Q · filed 2024-07-31 | $6.92M 10-Q · filed 2024-07-31 | $10.11M derived: sum of 3 quarters · filed 2025-02-26 | $12.24M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $3.37M 10-Q · filed 2024-05-08 | $6.55M derived: sum of 2 quarters · filed 2025-02-26 | $8.69M derived: sum of 3 quarters · filed 2025-02-26 | $9.41M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $5.32M derived: sum of 2 quarters · filed 2025-02-26 | $6.05M derived: sum of 3 quarters · filed 2025-02-26 | $6.37M 10-K · filed 2025-02-26 |
| 2022-09-30 | $2.13M 10-Q · filed 2023-11-01 | $2.86M derived: sum of 2 quarters · filed 2023-11-01 | $3.18M 10-Q · filed 2023-11-01 | $4.52M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $724.00K 10-Q · filed 2023-08-02 | $1.05M 10-Q · filed 2023-08-02 | $2.38M derived: sum of 3 quarters · filed 2024-03-05 | $2.83M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $322.00K 10-Q · filed 2023-05-09 | $1.66M derived: sum of 2 quarters · filed 2024-03-05 | $2.11M derived: sum of 3 quarters · filed 2024-03-05 | $2.13M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $1.34M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $1.79M derived: sum of 2 quarters · filed 2024-03-05 | $1.81M derived: sum of 3 quarters · filed 2024-03-05 | $1.84M 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $453.00K 10-Q · filed 2022-11-09 | $473.00K derived: sum of 2 quarters · filed 2022-11-09 | $503.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $20.00K 10-Q · filed 2022-07-27 | $50.00K 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $30.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $1.52M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $5.54M 10-K/A · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |